Skip to main content
Normal View

Medicinal Products Reimbursement

Dáil Éireann Debate, Thursday - 28 February 2019

Thursday, 28 February 2019

Questions (157, 158, 159)

Lisa Chambers

Question:

157. Deputy Lisa Chambers asked the Minister for Health the detail of the recommendation the rare disease technical review committee gave on Spinraza, that is, to reimburse the drug; and if he will make a statement on the matter. [10112/19]

View answer

Lisa Chambers

Question:

158. Deputy Lisa Chambers asked the Minister for Health the detail of the recommendation the HSE drugs group gave on Spinraza to reimburse the drug; and if he will make a statement on the matter. [10113/19]

View answer

Lisa Chambers

Question:

159. Deputy Lisa Chambers asked the Minister for Health the detail of the recommendation the HSE leadership team gave on Spinraza to reimburse the drug; and if he will make a statement on the matter. [10114/19]

View answer

Written answers

I propose to take Questions Nos. 157 to 159, inclusive, together.

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for the pricing and reimbursement of medicines; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.

Top
Share